Home › Sistema immunitario e disturbi › New York › New York City
Studi clinici su Sistema immunitario e disturbi a New York City, NY
12 studi su Sistema immunitario e disturbi cercano partecipanti presso sedi a New York City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
In reclutamentoFase 3
- Memorial Sloan Kettering Cancer Center, New York
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
In reclutamentoFase 3
- Memorial Sloan Kettering Cancer Center, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
In reclutamentoFase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Abatacept for the Treatment of Giant Cell Arteritis
In reclutamentoFase 3
- Hospital for Special Surgery, New York
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
In reclutamentoFase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
In reclutamentoFase 2
- Inmagene Site 21, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
In reclutamentoFase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
In reclutamentoFase 2
- Columbia University Irving Medical Center, New York
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
In reclutamentoFase 1/2
- Columbia University, New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
In reclutamentoFase 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Biologics And Clinical Immunology Cohort at Sinai
In reclutamentoStudio osservazionale
- Mount Sinai, New York
Studi su Sistema immunitario e disturbi in altre città
- Washington, DC13 studi
- Philadelphia, PA10 studi
- Boston, MA10 studi
- Atlanta, GA9 studi
- Portland, OR9 studi
- Houston, TX9 studi
- Cleveland, OH8 studi
- Los Angeles, CA8 studi
- Chicago, IL8 studi
- Milwaukee, WI6 studi
- Seattle, WA6 studi
- Cedar Rapids, IA6 studi
Altri studi a New York City
- Cancro al seno136 studi
- Cancro del polmone non a piccole cellule121 studi
- Cancro (tutti i tipi)109 studi
- Cancro alla prostata103 studi
- Cancro metastatico93 studi
- Cancro colorettale78 studi
- Cancro ovarico69 studi
- Cancro ai polmoni60 studi
- Mieloma multiplo60 studi
- Cancro pancreatico60 studi
- Cancro dell'endometrio52 studi
- Leucemia mieloide acuta51 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.